Regeneron Pharmaceuticals Expands Board of Directors with Renowned Scientist Marc Tessier-Lavigne

Strategic Insights -

Regeneron Pharmaceuticals, Inc. has announced the election of Marc Tessier-Lavigne, Ph.D. to its expanded Board of Directors. Dr. Tessier-Lavigne, current President of The Rockefeller University, brings a wealth of experience in leading drug-discovery programs and a strong track record of scientific innovation. His appointment is seen as a strategic move for Regeneron as it transforms into a fully integrated biotechnology company. With his expertise in neuroscience and drug development, Dr. Tessier-Lavigne will contribute to guiding scientific and product development decisions at Regeneron.

Key Takeaways:

  • Dr. Marc Tessier-Lavigne, President of The Rockefeller University, joins Regeneron's Board of Directors, bringing 10 years of experience in leading drug-discovery programs at Genentech.
  • Dr. Tessier-Lavigne has an outstanding track record for pioneering the identification of molecules that direct neuronal circuit formation in the mammalian brain and spinal cord.
  • He will contribute to Regeneron's scientific and product development decisions, leveraging his expertise in neuroscience and drug development.
  • As a world leader in brain development research, Dr. Tessier-Lavigne is well-positioned to guide Regeneron's efforts in discovering and developing innovative therapeutics.
  • Dr. Tessier-Lavigne obtained his Ph.D. from University College London and performed postdoctoral work at the Medical Research Council (United Kingdom) Developmental Neurobiology Unit and at Columbia University.
  • He has been a faculty member at the University of California, San Francisco, and Stanford University, and is a Howard Hughes Medical Institute investigator.
  • Dr. Tessier-Lavigne is the recipient of numerous scientific awards and is an elected member of the U.S. National Academy of Sciences and its Institute of Medicine.

Statistics:

  • Mar 2003: Dr. Tessier-Lavigne joined Genentech, where he oversaw 1,400 people in disease research and drug discovery.
  • 10 years: Dr. Tessier-Lavigne's experience in leading drug-discovery programs at Genentech.
  • 1,400: The number of people Dr. Tessier-Lavigne oversaw in disease research and drug discovery at Genentech.

Sources:

  • "Regeneron Pharmaceuticals Expands Board of Directors." _Biotech Week_, 2011.
  • "Marc Tessier-Lavigne Joins Regeneron Pharmaceuticals, Inc. Board of Directors." _NewsRx.com_.